Abstract
Multiple sclerosis (MS) is an immunopathic disease that is characterized pathologically by focal areas of inflammation and demyelination in the central nervous system white matter. As the immunologic nature of MS has become better defined, it has been possible to consider rational therapies to be tested in a scientifically rigorous fashion in well defined populations of MS patients (Chapters 2 and 3). One such treatment is copolymer 1, which has now been tested in a small preliminary open study, two well controlled pilot trials and, recently, a large multicenter Phase III investigation. Each of these trials has provided significant information about the clinical value of copolymer 1 and has clarified the excellent patient tolerance of the therapy. This chapter will review the structure and findings of these four sequential clinical trials.
Dr Bornstein died in September 1995. His contributions to advances in the treatment of multiple sclerosis were important, and we ask the reader to join us by pausing to remember him. (Eds.)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abramsky O, Teitelbaum D, Arnon R (1977) Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and acute disseminated encephalomyelitis: preliminary report. J Neurol Sci 31: 433–438
Anderson S, Auguier A, Hauck W et al. (1980) Statistical methods for comparative studies. Wiley, New York, pp 199–214
Arnon R (1981) Experimental allergic encephalomyelitis: susceptibility and suppression. Immunol Rev 55: 5–30
Arnon R, Teitelbaum D (1980) Desensitization of experimental allergic encephalomyelitis with synthetic peptide analogues. In: Davison AN, Cuzner ML (eds) The suppression of experimental allergic encephalomyelitis and multiple sclerosis. Academic Press, New York, pp 105–117
Bornstein MB, Miller A, Teitelbaum D, Arnon R et al. (1982) Multiple sderosis: trial of a synthetic polypeptide. Ann Neurol 11: 317–319
Bornstein MB, Miller A, Slagle S et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317: 408–414
Bornstein MB, Miller A, Slagle S et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41: 533–539
Fridkis-Hareli M, Teitelbaum D, Gurevitch E et al. (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to dass II major histocompatibility complex molecules on living antigen presenting cells: specificity and promiscuity. Proc Natl Acad Sci USA 91: 4872–4876
Hauser SL, Dawson DM, Lehrich JR et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308: 173–180
Johnson K, Brooks BR, Cohen JA et al. (1995) Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268–1276
Keith AB, Arnon R, Teitelbaum D et al. (1979) The effect of Cop 1, a synthetic polypeptide on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci 42: 267–274
Kurtzke JF (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5: 580–583
Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452
Lando Z, Teitelbaum D, Arnon R (1979) Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 123: 2156–2160
Milo R, Panitch H (1995) Additive effects of copolymer-1 and interferon beta-lb on the immune responses to myelin basic protein. J Neuroimmunol 61: 185–193
Poser CM, Patty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227–231
Racke MK, Martin R, McFarland H, Fritz RB (1992) Copolymer 1-induced inhibition of antigen- specific T-cell activation: interference with antigen presentation. J Neuroimmunol 37: 75–84
Teitelbaum D, Meshorer A, Hirshfeld T et al. (1971) Suppression of experimental allergic encephalo-myelitis by a synthetic polypeptide. Eur J Immunol 1: 242–248
Teitelbaum D, Webb C, Meshorer A et al. (1973) Suppression by synthetic polypeptides of experi-mental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol 3: 273–279
Teitelbaum D, Webb C, Bree M et al. (1974) Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 3: 256–262
Teitelbaum D, Aharoni R, Sela M, Arnon R (1991) Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 88: 9528–9532
Teitelbaum D, Milo R, Amon R, Sela M (1992) Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Nail Acad Sci USA 89: 137–141
Webb C, Teitelbaum D, Arnon R et al. (1973) In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experi-mental allergic encephalomyelitis. Eur J Immunol 3: 279–286
Webb C, Teitelbaum D, Herz A et al. (1976) Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry 13: 333–337
Weinshenker BG, Bass B, Rice G, Noseworthy J et al. (1989) The natural history of multiple sclerosis: a geographically based study: 2. Predictive value of the early clinical course. Brain 112: 1419–1428
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag London Limited
About this chapter
Cite this chapter
Johnson, K.P., Bornstein, M.B. (1996). Treatment of Multiple Sclerosis with Copolymer 1. In: Goodkin, D.E., Rudick, R.A. (eds) Multiple Sclerosis. Springer, London. https://doi.org/10.1007/978-1-4471-1271-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-4471-1271-6_13
Publisher Name: Springer, London
Print ISBN: 978-1-85233-033-0
Online ISBN: 978-1-4471-1271-6
eBook Packages: Springer Book Archive